Vor Biopharma Stock Current Valuation
| VOR Stock | USD 1.00 0.02 1.98% |
Valuation analysis of Vor Biopharma helps investors to measure Vor Biopharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of 12/12/2024, Enterprise Value Over EBITDA is likely to drop to -1.43. In addition to that, Enterprise Value Multiple is likely to drop to -1.43. Fundamental drivers impacting Vor Biopharma's valuation include:
Price Book 0.9507 | Enterprise Value 41.5 M | Enterprise Value Ebitda (3.09) |
Undervalued
Today
Please note that Vor Biopharma's price fluctuation is risky at this time. Calculation of the real value of Vor Biopharma is based on 3 months time horizon. Increasing Vor Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Vor stock is determined by what a typical buyer is willing to pay for full or partial control of Vor Biopharma. Since Vor Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Vor Stock. However, Vor Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0 | Real 4.54 | Target 15.44 | Hype 0.98 | Naive 1.12 |
The intrinsic value of Vor Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Vor Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Vor Biopharma helps investors to forecast how Vor stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vor Biopharma more accurately as focusing exclusively on Vor Biopharma's fundamentals will not take into account other important factors: Vor Biopharma Company Current Valuation Analysis
Vor Biopharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Vor Biopharma Current Valuation | 41.47 M |
Most of Vor Biopharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vor Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Vor Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Vor Biopharma is extremely important. It helps to project a fair market value of Vor Stock properly, considering its historical fundamentals such as Current Valuation. Since Vor Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vor Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vor Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Vor Current Valuation Historical Pattern
Today, most investors in Vor Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vor Biopharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Vor Biopharma current valuation as a starting point in their analysis.
Vor Biopharma Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Vor Biopharma has a Current Valuation of 41.47 M. This is 99.71% lower than that of the Biotechnology sector and 99.11% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.75% higher than that of the company.
Vor Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vor Biopharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vor Biopharma could also be used in its relative valuation, which is a method of valuing Vor Biopharma by comparing valuation metrics of similar companies.Vor Biopharma is currently under evaluation in current valuation category among its peers.
Vor Fundamentals
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 41.47 M | ||||
| Shares Outstanding | 68.67 M | ||||
| Shares Owned By Insiders | 1.17 % | ||||
| Shares Owned By Institutions | 81.20 % | ||||
| Number Of Shares Shorted | 1.41 M | ||||
| Price To Book | 0.95 X | ||||
| EBITDA | (114.37 M) | ||||
| Net Income | (117.86 M) | ||||
| Cash And Equivalents | 151.09 M | ||||
| Cash Per Share | 3.97 X | ||||
| Total Debt | 35.66 M | ||||
| Debt To Equity | 0.24 % | ||||
| Current Ratio | 12.95 X | ||||
| Book Value Per Share | 2.22 X | ||||
| Cash Flow From Operations | (100.29 M) | ||||
| Short Ratio | 2.99 X | ||||
| Earnings Per Share | (1.64) X | ||||
| Target Price | 13.21 | ||||
| Number Of Employees | 168 | ||||
| Beta | -0.41 | ||||
| Market Capitalization | 71.42 M | ||||
| Total Asset | 198.13 M | ||||
| Retained Earnings | (340.08 M) | ||||
| Working Capital | 125.23 M | ||||
| Net Asset | 198.13 M |
About Vor Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vor Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vor Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vor Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Vor Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vor Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vor Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Vor Stock
The ability to find closely correlated positions to Vor Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vor Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vor Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vor Biopharma to buy it.
The correlation of Vor Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vor Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vor Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vor Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.